Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $268M (up 9.7% year over year) with net income of $4M.
Q1 2026 key financials · XBRL
- Revenue
- $268M
- +9.7% YoY
- Net income
- $4M
- −80.8% YoY
- Operating margin
- -1.7%
- EPS (diluted)
- $0.02
- −81.8% YoY
Source: XBRL data from the ACADIA PHARMACEUTICALS INC (ACAD) Q1 2026 10-Q on SEC EDGAR. USD.
ACADIA PHARMACEUTICALS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $268.1M, up $23.8M YoY from $244.3M
- DAYBUE best performer at $101.2M, up $16.6M YoY
- NUPLAZID $166.9M, up $7.2M YoY
- Product-cost margin 91% vs 92% YoY
- Cash and investments $851.5M, up $31.8M; operating cash flow $34.0M vs $20.3M
- Outlook: funding planned operations through and beyond next 12 months; macroeconomic volatility and financing access remain headwinds
Risk Factors
- No explicit new risk factor identified; section carries forward commercialization, regulatory, reimbursement, and development risks
- EU Health Technology Assessment Regulation effective January 12, 2025, creating evolving evidence requirements and potential reimbursement delays
- DAYBUE post-marketing obligations include renal-impairment, carcinogenicity, and drug-interaction studies, with one of five PMRs released
- Limited specialty-distributor and specialty-pharmacy network creates near-term product-access and commercialization risk
- NUPLAZID could face Medicare price negotiation in 2029, subject to specified small-manufacturer protections and discount phase-in in 2029–2030
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACADIA PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.